Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

Evergreen is a clinical-stage radiop Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for ...

Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.

In January, Lantheus Holdings (NASDAQ:LNTH) signed a definitive agreement to acquire Evergreen Theragnostics, a clinical-stage radiopharmaceutical company, in an all-cash deal. The agreement ...

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

The acquisition of Evergreen Theragnostics will enhance the Company's position as an end-to-end fully integrated radiopharmaceutical leader, expanding manufacturing and R&D capabilities. The ...

Lantheus Holdings, Inc. (NASDAQ ... On January 28, the company announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash deal, which includes an upfront payment of $ ...

The firm has a market cap of $5.66 billion, a P/E ratio of 13.54 and a beta of 0.44. Lantheus has a 52-week low of $56.06 and a 52-week high of $126.89. The business’s 50-day moving average ...

Brian Markison, CEO Evergreen Theragnostics is expected to add Octevy, a registrational stage PET radiodiagnostic that would complement Lantheus' therapeutic candidate, PNT2003. Both acquisitions ...